Details for New Drug Application (NDA): 209253
✉ Email this page to a colleague
NDA 209253 describes AMPHETAMINE, which is a drug marketed by Actavis Labs Fl Inc, Alkem Labs Ltd, Amneal Pharms, Aurolife Pharma Llc, Bionpharma, Cerovene Inc, Dr Reddys Labs Sa, Epic Pharma Llc, Glenmark Pharms Ltd, Granules, Lannett, Novast Labs, Prinston Inc, Rhodes Pharms, Senores Pharms, Specgx Llc, and Sun Pharm Inds Inc, and is included in seventeen NDAs. Additional details are available on the AMPHETAMINE profile page.
The generic ingredient in AMPHETAMINE is amphetamine sulfate. There are fifty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.
The generic ingredient in AMPHETAMINE is amphetamine sulfate. There are fifty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.
Summary for 209253
| Tradename: | AMPHETAMINE |
| Applicant: | Actavis Labs Fl Inc |
| Ingredient: | amphetamine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 209253
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Strength | EQ 3.1MG BASE | ||||
| Approval Date: | Jun 22, 2023 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Strength | EQ 6.3MG BASE | ||||
| Approval Date: | Jun 22, 2023 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Strength | EQ 9.4MG BASE | ||||
| Approval Date: | Jun 22, 2023 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
